A PYMNTS Company

FTC’s Second Request for additional information on Spectrum’s offer for Allos

By  |  May 10, 2012

The FTC has made a Second Request, for additional information and documentary material, on Spectrum Pharmaceutical’s proposed acquisition of Allos Therapeutics. As a result, Spectrum has extended the offer period for its tender offer to purchase all outstanding shares of common stock, from May 10 to May 24.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Spectrum is a biotech company that acquires, develops, and markets oncology and hematology drugs. Allos develops and commercializes cancer treatments.

    Full content: MarketWatch

     

    Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.